Login to Your Account



Casi expands TNBC testing in China; CFDA nod for phase II trials

By Cornelia Zou
Staff Writer

Wednesday, July 23, 2014

HONG KONG – A Chinese-focused U.S. biopharma company got the green light from the CFDA to carry out phase II trials for a new cancer drug.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription